@entity3243 is one cause of @entity459 , a condition in which there is @entity2741 and dysregulated hypersecretion of @entity461 . In normal, and in some @entity5 parathyroid cells, @entity461 secretion is mediated by the cell surface @entity460 -sensing receptor. We describe the first therapeutic use of a novel molecule, a calcimimetic, that has agonist action at the @entity460 -sensing receptor. A 78-yr-old @entity1 with @entity3243 was admitted with @entity2741 , markedly elevated @entity461 , and a change in mental status. He was treated for 17 days with conventional therapy, which included saline hydration, @entity1483 , @entity5279 , and @entity175 . This was ineffective, and on hospital day 18, calcimimetic at a dose of 50 mg, orally, every 6 h was added. On hospital day 25, the dose was increased to 100 mg, orally, every 6 h, and on hospital day 30, saline and @entity1483 were discontinued. He was discharged on hospital day 40. With several dose adjustments, he has been treated with monotherapy calcimimetic for over 600 days and has not required any other interventions for his @entity3243 . Mean daily precalcimimetic treatment values of serum ionized @entity460 and @entity461 were 1.83 mmol/L and 872 pg/mL, respectively. During hospitalization, at the lower dose of calcimimetic, @entity460 and @entity461 decreased to 1.67 mmol/L and 538 pg/mL; with the higher dose they further decreased to 1.51 mmol/L and 444 pg/mL. Since discharge, and despite increasing levels of @entity461 , serum @entity460 has remained high, but lower than the admission level and acutely responsive to changes in calcimimetic doses. This compound, a calcimimetic, the first of a new class of compounds with activity at the @entity460 -sensing receptor, has been used to treat a @entity1 with @entity3243 . During 2 yr of treatment, no adverse clinical effects have been observed, and it appears to have been effective at controlling @entity2741 .

Treatment of @entity2741 secondary to XXXX with a novel calcimimetic agent.

@entity1 :: ('9606', 'Species') :: ['patient', 'man'] @entity459 :: ('MESH:D049950', 'Disease') :: ['primary hyperparathyroidism'] @entity175 :: ('MESH:D002116', 'Chemical') :: ['calcitonin'] @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate'] @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplastic'] @entity1483 :: ('MESH:D005665', 'Chemical') :: ['furosemide'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity3243 :: ('MESH:D010282', 'Disease') :: ['Parathyroid carcinoma', 'parathyroid carcinoma'] @entity461 :: ('5741', 'Gene') :: ['PTH']
@entity3243 :: (MESH:D010282,Disease) :: ['parathyroid carcinoma']
